• Biomarkers Pinpoint Resistant Prostate Cancer That May Benefit From Addition of Apalutamide

    1 month ago - By Medscape

    Biomarkers can be used to identify patients with prostate cancer refractory to first-line androgen deprivation therapy who might benefit from the addition of apalutamide to standard treatments, researchers say.
    Reuters Health Information
    Read more ...

     

  • FDA grants breakthrough designation to radioligand therapy for advanced prostate cancer

    FDA grants breakthrough designation to radioligand therapy for advanced prostate cancer

    1 month ago - By Healio

    The FDA granted breakthrough therapy designation to 177Lu-PSMA-617 for treatment of metastatic castration-resistant prostate cancer, according to the agent's manufacturer.
    177Lu-PSMA-617 is an investigational radioligand therapy.
    During radioligand therapy, a targeting compound that binds to markers expressed by tumors is combined with a radioactive isotope. This approach allows for targeted delivery of radiation to the tumor and surrounding microenvironment while limiting damage to nearby healthy tissue.
    The randomized phase 3 VISION study evaluated the addition of
    Read more ...